Dr. Douglas Scherr - Urologic Oncology at Weill Cornell
In this video, Dr. Douglas Scherr of discusses the clinical approach for the diagnosis and treatment of complex urologic cancers in the Department of Urology at Weill Cornell Medicine.
First Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at Incurable Prostate Cancer
NewYork-Presbyterian and Weill Cornell Medicine clinicians in progress on Phase 1 clinical trial of PSMA-Targeted Therapeutic Agent for the Treatment for Metastatic Prostate Cancer
NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the U.S. that uses a small molecule, 177Lu-PSMA-617, to treat men with progressive prostate cancer that has spread beyond the prostate, or is metastatic, and is no longer responding to hormonal therapy.
Blood in the Urine - Study Challenges the Standard Diagnostic Approach
Combining kidney ultrasound with a visual examination of the bladder and urethra appears to be the most cost-effective way to screen for cancers of the genitourinary tract in people with microscopic amounts of blood in their urine, according to a study from Weill Cornell Medicine and NewYork-Presbyterian researchers.
Incidence of Metastatic Prostate Cancer in Older Men Increases Following Drop in PSA Screening
The incidence of metastatic prostate cancer in older men is rising after reaching an all-time low in 2011, according to new research from Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest a correlation between the increase and a change in prostate cancer screening guidelines recommending against routine prostate-specific antigen (PSA) testing.
Prostate Fusion Biopsy - Patient Experience: Dr. Jim Hu - Weill Cornell Medicine
This video was filmed for educational purposes, to give patients a better idea of what to expect when scheduled for a prostate fusion biopsy.
Significant decrease seen in prostate biopsy, radical prostatectomy procedures following recommendations
In a study published online by JAMA Surgery, Jim C. Hu, M.D., M.P.H., Joshua A. Halpern, M.D., M.S., of Weill Cornell Medicine, New York, and colleagues examined effects on practice patterns in prostate cancer diagnosis and treatment following the U.S. Preventative Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA) screening in 2012.
Significant decrease seen in prostate biopsy, radical prostatectomy procedures following recommendations
In a study published online by JAMA Surgery, Jim C. Hu, M.D., M.P.H., Joshua A. Halpern, M.D., M.S., of Weill Cornell Medicine, New York, and colleagues examined effects on practice patterns in prostate cancer diagnosis and treatment following the U.S. Preventative Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA) screening in 2012.
What does the future hold for robotics in medicine? (92Y Panel with Weill Cornell Medicine)
What does the future hold for robotics in medicine?
Medical experts from Weill Cornell Medicine discuss this fascinating topic. Joining us for this panel are Cheguevara Afaneh, MD; T. Sloane Guy, MD; Jim Hu, MD; Jeffrey Port, MD; Douglas Scherr, MD; and Joel Stein, MD, with moderator Dr. Max Gomez from WCBS-TV.
The past decade has produced tremendous advances in the use of robotics across clinical areas, vastly expanding the horizons of disease management.
Timothy McClure
Dr. Timothy McClure joined Brady Urology as a full time faculty member during the summer of 2016, providing his expertise to both the Departments of Urology & Radiology. Dr. McClure is an expert in imaging, image-guided therapy, and the minimally invasive treatment of urologic disease. Dr. McClure brings a unique training background to the department as he is not only a urologist, but also a board-certified radiologist who is fellowship trained in vascular and interventional radiology. Dr.
Dr. Barbieri on SPOP Mutations in Prostate Cancer (OncLive)
Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer genomics, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New-York Presbyterian, discusses the implications of SPOP mutations in patients with prostate cancer.
